| __timestamp | AstraZeneca PLC | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 4042025 |
| Thursday, January 1, 2015 | 11451000000 | 5279557 |
| Friday, January 1, 2016 | 9739000000 | 8073913 |
| Sunday, January 1, 2017 | 10543000000 | 44864073 |
| Monday, January 1, 2018 | 10362000000 | 53488904 |
| Tuesday, January 1, 2019 | 11848000000 | 65896361 |
| Wednesday, January 1, 2020 | 11693000000 | 69968267 |
| Friday, January 1, 2021 | 15680000000 | 92047281 |
| Saturday, January 1, 2022 | 18955000000 | 131819000 |
| Sunday, January 1, 2023 | 18025000000 | 87501000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, AstraZeneca PLC has consistently outpaced Pharming Group N.V. in SG&A spending, reflecting its expansive global operations. From 2014 to 2023, AstraZeneca's SG&A expenses grew by approximately 35%, peaking in 2022. In contrast, Pharming Group's expenses, though significantly lower, increased by over 300% during the same period, indicating rapid scaling efforts. Notably, AstraZeneca's expenses in 2023 were about 200 times higher than Pharming's, underscoring its market dominance. This analysis highlights the strategic financial management differences between a pharmaceutical giant and a growing biotech firm. As the industry evolves, monitoring these trends offers insights into operational strategies and market positioning.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
Gross Profit Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
AstraZeneca PLC or Bio-Techne Corporation: Who Manages SG&A Costs Better?
AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs PTC Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Comparing SG&A Expenses: Viatris Inc. vs Pharming Group N.V. Trends and Insights
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Comparing SG&A Expenses: Pharming Group N.V. vs Xenon Pharmaceuticals Inc. Trends and Insights
Pharming Group N.V. vs HUTCHMED (China) Limited: SG&A Expense Trends